Azacitidine
- Generic Name
- Azacitidine
- Brand Names
- Onureg, Vidaza, Azacitidine Accord, Azacitidine betapharm, Azacitidine Mylan, Azacitidine Kabi
- Drug Type
- Small Molecule
- Chemical Formula
- C8H12N4O5
- CAS Number
- 320-67-2
- Unique Ingredient Identifier
- M801H13NRU
- Background
Azacitidine is a pyrimidine nucleoside analogue with anti-neoplastic activity. It differs from cytosine by the presence of nitrogen in the C5-position, key in its hypomethylating activity. Two main mechanisms of action have been proposed for azacitidine. One of them is the induction of cytotoxicity. As an analogue of cytidine, it is able to incorporate into ...
- Indication
Azacitidine (for subcutaneous or intravenous use) is indicated for the treatment of adult patients with the following French-American-British (FAB) myelodysplastic syndrome (MDS) subtypes: refractory anemia (RA) or refractory anemia with ringed sideroblasts (RARS) (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemi...
- Associated Conditions
- Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Refractory Anemia, Refractory Anemia With Excess Blasts in Transformation, Refractory Anemia With Excess of Blasts (RAEB), Refractory Anemia With Ringed Sideroblasts, Newly diagnosed Juvenile Myelomonocytic Leukaemias (JMML)
- Associated Therapies
- -
A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2023-05-09
- Last Posted Date
- 2024-11-11
- Target Recruit Count
- 58
- Registration Number
- NCT05849662
- Locations
- 🇺🇸
Children's National Medical Center, Washington, District of Columbia, United States
🇺🇸Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸University of California San Francisco, San Francisco, California, United States
A Phase Ib Trial of Azacitidine, Venetoclax and Allogeneic NK Cells for Acute Myeloid Leukemia (ADVENT-AML)
- Conditions
- Interventions
- First Posted Date
- 2023-04-28
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 32
- Registration Number
- NCT05834244
- Locations
- 🇺🇸
M.D. Anderson Cancer Center, Houston, Texas, United States
A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)
- Conditions
- Interventions
- First Posted Date
- 2023-04-25
- Last Posted Date
- 2024-01-11
- Lead Sponsor
- PureTech
- Target Recruit Count
- 90
- Registration Number
- NCT05829226
- Locations
- 🇺🇸
Mass. General Hospital-Harvard, Boston, Massachusetts, United States
🇺🇸Virginia Commonwealth University Medical Center, Richmond, Virginia, United States
🇺🇸Baptist Health South Florida-Miami Cancer Institute, Miami, Florida, United States
Chidamide, Azacitidine Combined With GM Regimen for Relapsed and Refractory DLBCL Patients
- Conditions
- Interventions
- First Posted Date
- 2023-04-21
- Last Posted Date
- 2023-04-21
- Target Recruit Count
- 23
- Registration Number
- NCT05823701
- Locations
- 🇨🇳
the First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
Magrolimab in Combination With Azacitidine After Allogeneic HCTin Treating Patients With High-Risk AML or MDS
- Conditions
- Interventions
- First Posted Date
- 2023-04-21
- Last Posted Date
- 2024-01-02
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 44
- Registration Number
- NCT05823480
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Selinexor and HAAG With/Without HMA in Relapsed/Refractory Acute Leukemia (AML) Patients
- Conditions
- Interventions
- First Posted Date
- 2023-04-07
- Last Posted Date
- 2023-05-06
- Target Recruit Count
- 20
- Registration Number
- NCT05805072
- Locations
- 🇨🇳
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
A Study Using Subject-specific MRD to Adopt Treatment After HSCT for Subjects With MDS
- First Posted Date
- 2023-03-29
- Last Posted Date
- 2023-12-05
- Lead Sponsor
- Karolinska University Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT05788679
- Locations
- 🇸🇪
Department of Hematology, Karolinska University Hospital, Stockholm, Sweden
PD-1 Inhibitor, Azacitidine and Low-dose DLI in AML Relapse After Allo-HSCT
- Conditions
- Interventions
- First Posted Date
- 2023-03-16
- Last Posted Date
- 2024-05-14
- Target Recruit Count
- 43
- Registration Number
- NCT05772273
- Locations
- 🇨🇳
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination with Venetoclax/Azacitidine, Venetoclax, or 7+3 in Patients with AML
- Conditions
- Interventions
- First Posted Date
- 2023-02-21
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Kura Oncology, Inc.
- Target Recruit Count
- 212
- Registration Number
- NCT05735184
- Locations
- 🇺🇸
Moores UC San Diego Cancer Center, La Jolla, California, United States
🇺🇸USC University of Southern California / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸UCLA - Bowyer Oncology Center, Los Angeles, California, United States
Adaptive Treatment for Acute Myeloid Leukemia Based on D14 MRD Results
- First Posted Date
- 2023-02-21
- Last Posted Date
- 2023-03-15
- Lead Sponsor
- Shanghai Tong Ren Hospital
- Target Recruit Count
- 58
- Registration Number
- NCT05736978
- Locations
- 🇨🇳
Pla Navy Feature Medical Center, Shanghai, China
🇨🇳Shanghai Ruijin Hospital, Shanghai, China
🇨🇳Shanghai Tong Ren hospital, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.